ZIVO Bioscience to Present at The Microcap Conference 2025

ZIVO Bioscience, Inc. (OTCQB: ZIVO), a leader in the biotech and agtech sectors, will participate in The Microcap Conference 2025, scheduled for January 28-30, 2025, at the Borgata Hotel Casino & Spa in Atlantic City, New Jersey. The company's management team is set to deliver a corporate presentation on January 30 at 2:30 PM Eastern Time, where they will discuss recent advancements, their growth strategy, and potential investment opportunities.

ZIVO focuses on the research and development of innovative therapeutic, nutritional, and medicinal products derived from proprietary algal cultures. They have developed a robust intellectual property portfolio that includes proprietary strains of algae and bacteria, as well as biologically active molecules and complexes. Their cutting-edge production and cultivation techniques, combined with patented and patent-pending inventions, position ZIVO favorably for applications in both human and animal health.

The Microcap Conference is a key platform for public companies to engage with institutional and individual investors. By participating in this event, ZIVO aims to enhance its visibility in the investment community and provide insights into its future directions.

Investors interested in gaining a deeper understanding of ZIVO's innovative approaches and potential market impact are encouraged to attend the conference and take advantage of opportunities for one-on-one meetings with the company's leadership. To secure a spot at the event, participants can register via the conference's official website.

For more detailed information about ZIVO Bioscience and its recent developments, interested parties can visit the company's website at www.zivobioscience.com or contact their Investor Relations team. Through its participation in The Microcap Conference, ZIVO aims to solidify its position as a pivotal player in biotech research and product development.

As ZIVO Bioscience, Inc. (OTCQB: ZIVO) prepares to present at The Microcap Conference 2025, investors should take note of the company's significant potential in the biotech and agtech sectors. With a focus on developing therapeutic and nutritional products derived from proprietary algal cultures, ZIVO is positioned to capitalize on a growing market trend leaning towards sustainable and naturally derived health solutions.

ZIVO's participation in this high-profile conference provides a platform to showcase recent advancements in its R&D initiatives and highlight its robust intellectual property portfolio, which includes proprietary algal and bacterial strains. The upcoming presentation on January 30, 2025, offers an excellent opportunity for both institutional and individual investors to gain insights into the company’s growth strategy and future investment prospects.

Investors should closely monitor ZIVO's pipeline for developments in product candidates that could translate into substantial market opportunities, particularly in human and animal health. The increasing consumer demand for nutritional products with proven health benefits positions ZIVO favorably in the competitive landscape. Furthermore, as regulations around health supplements and bioproducts continue to evolve, companies with a strong IP base and innovative approaches, like ZIVO, may gain a first-mover advantage.

For those contemplating an investment, engaging in the one-on-one meetings offered during the conference can provide valuable insights into management’s vision and strategic goals. With a clear focus on building partnerships and expanding market presence, ZIVO's participation in this event may act as a catalyst for future growth.

Therefore, investors seeking exposure to biotech innovation should consider ZIVO Bioscience as a potential addition to their portfolios, particularly given its strong foundation and commitment to advancing health solutions through cutting-edge research.